Harris et al. found that single-agent trastuzumab results in a limited treatment benefit in ovarian cancers; however, a combination therapy including both chemotherapy drugs and HER2-targeted antibody provides a far better response [43]. Here, ERBB2 is linked to ovarian carcinoma.